Friday , June 22 2018
Home / Technology & Devices

Technology & Devices

FDA Approves World’s First Long-Term Implantable Continuous Glucose Monitoring System for Patients with Diabetes

The U.S. Food and Drug Administration today approved the Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to …

Read More »

Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in Metastatic Breast Cancer

SAN DIEGO, June 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed case report demonstrating the clinical utility of its …

Read More »

Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use. Physicians in the United States can now gain valuable information to help them identify cervical cancer patients who are most likely …

Read More »

Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose Hepatocellular Carcinoma

WASHINGTON, June 5, 2018 /PRNewswire/ — Researchers at Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic announced significant progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma (HCC), the most common cancer that originates in the liver.1 The researchers detailed their findings during …

Read More »

Amgen and MD Anderson Announce Two Collaboration Agreements to Accelerate Development of Various Cancer Therapies

THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen’s early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. The agreements combine Amgen therapies …

Read More »

Adaptive and Sanofi Collaborate to Use Adaptive’s clonoSEQ Assay in Active and Future Isatuximab Multiple Myeloma Trials

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced today that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to …

Read More »

Foundation Medicine and Merck Enter Immuno-Oncology Companion Diagnostics Collaboration

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop companion diagnostic tests for use with KEYTRUDA®(pembrolizumab), Merck’s anti-PD-1 therapy and the first approved immunotherapy for microsatellite instability (MSI) high or mismatch repair deficient solid tumors. The companion …

Read More »

Data From Multiple Studies Demonstrate “Real-World” Value of Veracyte’s Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced that early user-experience data from three independent studies demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) significantly increases the number of patients who can avoid unnecessary surgery in thyroid cancer diagnosis, compared to the original, market-leading Afirma Gene Expression Classifier. The …

Read More »

Emulate and AstraZeneca Partner to Develop Organs-on-Chips Technology to Improve Prediction of Safety and Efficacy or Drug Candidates

BOSTON–(BUSINESS WIRE)–Emulate, Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization. As part of the agreement, Emulate plans to co-locate scientists within AstraZeneca’s laboratories. The aim of this agreement is …

Read More »

Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis

mina SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to …

Read More »